Cardio-Oncology Education and Training: JACC Council Perspectives

Cardio-Oncology Education and Training: JACC Council Perspectives

The development of innovative cancer therapies has led to unprecedented improvement in survival outcomes and diverse treatment-related toxicities, including those with cardiovascular in nature. Aging population further increase the number of patients being treated for cancer, especially those with comorbidities. As existing and developing cardiovascular disease poses some the greatest risk of morbidity and mortality in patients with cancer.

Addressing the needs of complex cardiovascular patients has become increasingly important, which resulted in important for intersecting disciplines: cardio-oncology. Over the past decade, there has been a remarkable improvement of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum practice guidelines and training standards, although these are being actively pursued. In the document the board’s perspective, the authors describe the scope of practice in oncology and cardio-training requirements proposed, and the core competencies required. This document also serves as a road map to confirm cardio-oncology as a subspecialty of medicine.

The use of biomarkers to guide the selection of patients and therapies have gained a lot of attention to improving the scope and complexity of the selection of targeted therapy and immunotherapy. Clinical trials provide the basis for the discovery of biomarkers, which can then help in the development of new drugs. For that, a sample of cancer patients, including DNA, RNA, proteins, and metabolome isolated from cancerous tissue and blood or urine, is analyzed in a variety of ways to identify relevant biomarkers. In conjunction with the nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided tests rely immunohistochemistry biomarker-based proteins play an important role in cancer treatment. In this review, we discuss the current knowledge of DNA and protein biomarkers for cancer immunotherapy.

both the primary and recurrence of cancer in patients after resection of colorectal cancer: An analysis of the integrated test with the Japan Clinical Oncology Group: JCOG1702A

Background: Improved early detection and treatment have resulted in an increase in the number of long-term victims of colorectal cancer (CRC). For the victims, a second primary cancers and recurrences are important issues; However, the evidence for the study of appropriate control strategies limited.This remnants aims to determine the frequency and timing of a second primary cancer in patients after surgery to explore the appropriate control strategies using an integrated analysis of three large-scale randomized controlled trials in Japan.

Methods: The eligibility criteria of the three trials included histologically confirmed CRC and receive operations. Time, location and frequency of second primary cancers and recurrences investigated. risk factors associated with a second primary cancer were also examined. standard incidence ratio (SIR) of a second primary cancer in comparison to the national database of the Cancer Registry of Japan is expected.
Results: A total of 2824 patients were included in this study. The cumulative incidence of second primary cancers increased from time to time. SIR of each second primary cancer was 1.07 (95% CI: 0.94 to 1.21). SIR for second primary cancers intestine was 1.09 (95% CI: 0.79 to 1.47). The cumulative incidence of recurrence nearly reached a plateau at 3 years.

Conclusions: A strategy for the general supervision of the general population can be applied even to patients curatively resected CRC, as a second primary cancer risk is nearly the same as the general population.

 Cardio-Oncology Education and Training: JACC Council Perspectives
Cardio-Oncology Education and Training: JACC Council Perspectives

Adherence to Oral Anticancer Therapeutics in Gynecologic Oncology Population

Introduction: To get a better understanding of gynecologic oncology patient compliance with oral anticancer agents through both cross-sectional survey of compliance and qualitative interviews with patients and physicians about their experiences with the drug.
Methods: Participants were eligible completing the survey for this cross-sectional study that included an assessment of compliance, distress, quality of life, and health literacy. Each woman takes oral anticancer agent for gynecological malignancies in a tertiary academic medical center for 30 days or more to qualify. semi-structured qualitative interviews (n = 14) was then performed to explore the experience with oral anticancer agent. We also perform qualitative group interviews with doctors and nurse practitioners.

Results: One hundred women taking oral anticancer agent listed. Fifty-four percent reported perfect adherence to their treatment, 21% reported a vague compliance (indicating at least one nonadherent behavior in the previous 7 days), and 25% reported non-compliance (indicating more than one behavior nonadherent within 7 days in advance). Qualitative analysis identified five main themes: the ease of use compared to traditional therapies; drugs self-administered mental burden; the perceived importance of the drug; management of side effects; and the desire for physician communication consistent. common misperception stated in an interview health care professionals including the high adherence to oral medication and a belief that the cost is the biggest barrier to compliance.

anti-PLGF

YF-PA13760 100 ug
EUR 483.6
Description: Rabbit polyclonal to PLGF

Bovine Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-b-48T 48T
EUR 591.6
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-b-96T 96T
EUR 769.2
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Mu-48T 48T
EUR 380.4
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Mu-96T 96T
EUR 477.6
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Rat Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Ra-48T 48T
EUR 544.8
Description: A sandwich quantitative ELISA assay kit for detection of Rat Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Ra-96T 96T
EUR 704.4
Description: A sandwich quantitative ELISA assay kit for detection of Rat Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-b-48Tests 48 Tests
EUR 592.8

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-b-96Tests 96 Tests
EUR 820.8

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-48Tests 48 Tests
EUR 354

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-96Tests 96 Tests
EUR 480

Rat Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Ra-48Tests 48 Tests
EUR 540

Rat Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Ra-96Tests 96 Tests
EUR 746.4

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-b-48Tests 48 Tests
EUR 619.2

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-b-96Tests 96 Tests
EUR 859.2

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Mu-48Tests 48 Tests
EUR 368.4

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Mu-96Tests 96 Tests
EUR 501.6

Rat Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Ra-48Tests 48 Tests
EUR 564

Rat Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Ra-96Tests 96 Tests
EUR 781.2

Anti-PLGF antibody

STJ72011 100 µg
EUR 430.8

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 418.8

Anti-PLGF-2 Antibody

A1303-100
EUR 405.6

Anti-PLGF-2 Antibody

A1303-30T
EUR 175.2

Anti-PLGF/PGF Antibody

PA1066 100ug/vial
EUR 352.8

Polyclonal Goat Anti-PLGF Antibody

AMM05090G 0.1 mg
EUR 580.8
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-PLGF . This antibody is tested and proven to work in the following applications:

PlGF antibody

70R-12427 100 ug
EUR 523.2
Description: Rabbit polyclonal PlGF antibody

PlGF Antibody

5743-100
EUR 405.6

PlGF Antibody

5743-30T
EUR 175.2

PLGF protein

30R-2693 10 ug
EUR 390
Description: Purified recombinant Mouse PLGF protein

PLGF Antibody

49602-100ul 100ul
EUR 399.6

PLGF Antibody

49602-50ul 50ul
EUR 286.8

PLGF Antibody

R30247 100 ug
EUR 419

PLGF Antibody

R34945-100UG 100 ug
EUR 399

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 336

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 336

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 336

PLGF-1, human recombinant

4739-100
EUR 836.4

PLGF-1, human recombinant

4739-1000
EUR 3909.6

PLGF-1, human recombinant

4739-25
EUR 307.2

PLGF-2, human recombinant

4741-10
EUR 307.2

PLGF-2, human recombinant

4741-1000
EUR 4105.2

PLGF-2, human recombinant

4741-50
EUR 874.8

Human PLGF ELISA Kit

EHP0025 96Tests
EUR 625.2

PLGF ELISA KIT|Human

EF000015 96 Tests
EUR 826.8

Human PLGF ELISA kit

LF-EK50333 1×96T
EUR 777.6

PLGF-3 Human Recombinant

P1563-10 10 µg
EUR 211.2

PLGF-3 Human Recombinant

P1563-50 50 µg
EUR 661.2

Human C-Peptide ELISA Kit

DLR-C-Peptide-Hu-48T 48T
EUR 477.6
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human C-Peptide ELISA Kit

DLR-C-Peptide-Hu-96T 96T
EUR 613.2
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human C-Peptide ELISA Kit

RD-C-Peptide-Hu-48Tests 48 Tests
EUR 464.4

Human C-Peptide ELISA Kit

RD-C-Peptide-Hu-96Tests 96 Tests
EUR 638.4

Human C-Peptide ELISA Kit

RDR-C-Peptide-Hu-48Tests 48 Tests
EUR 484.8

Human C-Peptide ELISA Kit

RDR-C-Peptide-Hu-96Tests 96 Tests
EUR 667.2

PlGF-1 Antibody

5739-100
EUR 405.6

PlGF-1 Antibody

5739-30T
EUR 175.2

PLGF, murine recombinant

4743-10
EUR 294

PLGF, murine recombinant

4743-1000
EUR 6519.6

PLGF, murine recombinant

4743-50
EUR 907.2

PLGF Rabbit pAb

A1727-100ul 100 ul
EUR 369.6

PLGF Rabbit pAb

A1727-200ul 200 ul
EUR 550.8

PLGF Rabbit pAb

A1727-20ul 20 ul
EUR 219.6

PLGF Rabbit pAb

A1727-50ul 50 ul
EUR 267.6

PLGF Rabbit pAb

A16257-100ul 100 ul
EUR 369.6

PLGF Rabbit pAb

A16257-200ul 200 ul
EUR 550.8

PLGF Rabbit pAb

A16257-20ul 20 ul
EUR 219.6

PLGF Rabbit pAb

A16257-50ul 50 ul
EUR 267.6

PlGF Recombinant Protein

96-625 0.02 mg
EUR 651.3
Description: Placental growth factor (PGF) is also known as vascular endothelial growth factor-related protein, PLGF and PlGF2, is a member of the VEGF (vascular endothelial growth factor) sub-family - a key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PGF during pregnancy is the placental trophoblast. PGF is also expressed in many other tissues, including the villous trophoblast. PGF is actived in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. PlGF2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.

PLGF(PLGF93) Antibody

BNC040093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC040093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC040094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC040094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCB0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCB0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCB0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCB0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCP0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCP0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCR0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCR0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC940093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC940093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC940094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC940094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCA0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCA0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNUB0093-100 100uL
EUR 250.8
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL

PLGF(PLGF93) Antibody

BNUB0093-500 500uL
EUR 549.6
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL

PLGF(PLGF94) Antibody

BNUB0094-100 100uL
EUR 250.8
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL

PLGF(PLGF94) Antibody

BNUB0094-500 500uL
EUR 549.6
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL

PLGF(PLGF93) Antibody

BNCH0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC880093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC880093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC880094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC880094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL

PLGF Conjugated Antibody

C49602 100ul
EUR 476.4

PLGF(PLGF93) Antibody

BNC680093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC680093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC680094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC680094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC470093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC470093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC470094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC470094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC400093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC400093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC400094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC400094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

Polyclonal PlGF Antibody

AMR09382G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PlGF . This antibody is tested and proven to work in the following applications:

PLGF(PLGF93) Antibody

BNUM0093-50 50uL
EUR 474
Description: Primary antibody against PLGF(PLGF93), 1mg/mL

PLGF(PLGF94) Antibody

BNUM0094-50 50uL
EUR 474
Description: Primary antibody against PLGF(PLGF94), 1mg/mL

PLGF Polyclonal Antibody

A72122
  • EUR 302.50
  • EUR 423.50
  • 50 ul
  • 100 ul

PLGF Polyclonal Antibody

A72123
  • EUR 302.50
  • EUR 423.50
  • 50 ul
  • 100 ul

PLGF Polyclonal Antibody

A72122-050 50 ul
EUR 302.5

PLGF Polyclonal Antibody

A72122-100 100 ul
EUR 423.5

PLGF Polyclonal Antibody

A72123-050 50 ul
EUR 302.5

PLGF Polyclonal Antibody

A72123-100 100 ul
EUR 423.5

PLGF ELISA Kit (Human) (OKBB00242)

OKBB00242 96 Tests
EUR 621.6
Description: Description of target: The protein, also called PGF, is 149 amino acids long and shares 53% identity with the platelet-derived growth factor-like region of human VPF. And the N-glycosylated PLGF protein is secreted into the medium and that it functions as a dimer1. The PLGF gene is mapped to 14q24-q31. There are 3 isoforms of PGF, designated PGF1, PGF2, and PGF3. Only PGF2 is able to bind heparin. Additionally, PGF regulates inter- and intramolecular cross-talk between the VEGF receptor tyrosine kinases FLT1 and FLK12. It also can stimulate angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to VEGF3.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 1 pg/mL

Human PLGF PicoKine ELISA Kit

EK0490 96 wells
EUR 523.2
Description: For quantitative detection of human PLGF in cell culture supernates, serum, plasma(heparin, EDTA, citrate) and urine.

PLGF-2, human recombinant protein

P1056-.01 10 µg
EUR 360
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

PLGF-2, human recombinant protein

P1056-.05 50 µg
EUR 1052.4
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

PLGF-2, human recombinant protein

P1056-1 1 mg
EUR 4987.2
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

ELISA kit for Human PLGF

EK5213 96 tests
EUR 663.6
Description: Enzyme-linked immunosorbent assay kit for quantification of Human PLGF in samples from serum, plasma, tissue homogenates and other biological fluids.

Human PLGF ELISA kit (4X96T)

LF-EK50334 4×96T
EUR 2641.2

Recombinant Human PlGF-3 Protein

PROTP49763-6 25ug
EUR 380.4
Description: PlGF-3 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-3 is expressed exclusively in the placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-3 lacks heparin binding affinity. Recombinant human PlGF-3 is a 45.7 kDa disulfide-linked homodimeric protein of two 203 amino acid polypeptide chains.

Recombinant Human PlGF-1 Protein

PROTP49763-7 25ug
EUR 380.4
Description: PlGF-1 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-1 is expressed in placental tissues, colon and mammary carcinomas. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. Recombinant human PlGF-1 is a 29.7 kDa disulfide-linked homodimeric protein of two 132 amino acid polypeptide chains.

Recombinant Human PlGF-2 Protein

PROTP49763-8 25ug
EUR 380.4
Description: PLGF-2 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PLGF-2 is expressed in umbilical vein endothelial cells and placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-2 also signals through Neuropilin (NP-1) and can bind with high affinity to heparin. Recombinant human PLGF-2 is a 34.0 kDa disulfide-linked homodimeric protein of two 150 amino acid polypeptide chains.

Human Placenta Growth Factor (PLGF) Protein

20-abx068556
  • EUR 844.80
  • EUR 343.20
  • EUR 2598.00
  • EUR 994.80
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

PlGF-1 Recombinant Protein

40-151-0005mg 0.005 mg
EUR 311.1
Description: PlGF-1 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-1 is expressed in placental tissues, colon and mammary carcinomas. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. Recombinant human PlGF-1 is a 29.7 kDa disulfide-linked homodimeric protein of two 131 amino acid polypeptide chains.

PlGF-1 Recombinant Protein

40-151-0025mg 0.025 mg
EUR 437.1
Description: PlGF-1 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-1 is expressed in placental tissues, colon and mammary carcinomas. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. Recombinant human PlGF-1 is a 29.7 kDa disulfide-linked homodimeric protein of two 131 amino acid polypeptide chains.

PlGF-2 Recombinant Protein

40-196-0005mg 0.005 mg
EUR 311.1
Description: PLGF-2 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PLGF-2 is expressed in umbilical vein endothelial cells and placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-2 also signals through Neuropilin (NP-1) and can bind with high affinity to heparin. Recombinant human PLGF-2 is a 34.0 kDa disulfide-linked homodimeric protein of two 150 amino acid polypeptide chains.

PlGF-2 Recombinant Protein

40-196-0025mg 0.025 mg
EUR 437.1
Description: PLGF-2 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PLGF-2 is expressed in umbilical vein endothelial cells and placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-2 also signals through Neuropilin (NP-1) and can bind with high affinity to heparin. Recombinant human PLGF-2 is a 34.0 kDa disulfide-linked homodimeric protein of two 150 amino acid polypeptide chains.

Conclusion: Nearly half of the patients surveyed reported vague or non-compliance with their oral anticancer agent. Qualitative interviews identified several important themes, many of which are not recognized by physicians and nurse practitioners. These findings highlight the need for the patient and health care professional interventions to improve patient adherence.